Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
Article in Scientific Reports (January 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Scientific Reports (January 2024)
Preprint in Research Square (May 2023)